Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) beyond week 52: Data from the Phase II TOMORROW trial

Authors :: Toshio Kimura
U Costabel
Zuojun Xu
Susanne Stowasser
M Selman
L Richeldi
Christoph Hallmann
Source :: Pneumologie. 70
Publication Year :: 2016
Publisher :: Georg Thieme Verlag KG, 2016.

Subjects :: Pulmonary and Respiratory Medicine
chemistry.chemical_compound
medicine.medical_specialty
Idiopathic pulmonary fibrosis
Pediatrics
chemistry
business.industry
Internal medicine
medicine
Nintedanib
In patient
medicine.disease
business

Tools